SMT201300077B - Derivati di ciclopropilammide diretti al recettoredi istamina H3 - Google Patents

Derivati di ciclopropilammide diretti al recettoredi istamina H3

Info

Publication number
SMT201300077B
SMT201300077B SM201300077T SM201300077T SMT201300077B SM T201300077 B SMT201300077 B SM T201300077B SM 201300077 T SM201300077 T SM 201300077T SM 201300077 T SM201300077 T SM 201300077T SM T201300077 B SMT201300077 B SM T201300077B
Authority
SM
San Marino
Prior art keywords
histamine
receptor
derivatives directed
cyclopropylamide
cyclopropylamide derivatives
Prior art date
Application number
SM201300077T
Other languages
English (en)
Italian (it)
Inventor
Andrew Griffin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300077(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SMT201300077B publication Critical patent/SMT201300077B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM201300077T 2009-02-20 2013-07-04 Derivati di ciclopropilammide diretti al recettoredi istamina H3 SMT201300077B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15406709P 2009-02-20 2009-02-20
PCT/SE2010/050191 WO2010096011A1 (en) 2009-02-20 2010-02-19 Cyclopropyl amide derivatives targeting the histamine h3 receptor

Publications (1)

Publication Number Publication Date
SMT201300077B true SMT201300077B (it) 2013-09-06

Family

ID=42631518

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300077T SMT201300077B (it) 2009-02-20 2013-07-04 Derivati di ciclopropilammide diretti al recettoredi istamina H3

Country Status (39)

Country Link
US (3) US8993577B2 (enExample)
EP (1) EP2398780B1 (enExample)
JP (2) JP5666480B2 (enExample)
KR (1) KR20110126628A (enExample)
CN (2) CN102405213B (enExample)
AR (1) AR075531A1 (enExample)
AU (1) AU2010216454B2 (enExample)
BR (1) BRPI1007817A2 (enExample)
CA (1) CA2752796A1 (enExample)
CO (1) CO6400219A2 (enExample)
CR (1) CR20110447A (enExample)
CU (2) CU20110161A7 (enExample)
DK (1) DK2398780T3 (enExample)
DO (1) DOP2011000270A (enExample)
EA (2) EA020093B1 (enExample)
EC (1) ECSP11011280A (enExample)
ES (1) ES2416464T3 (enExample)
HK (1) HK1208348A1 (enExample)
HN (1) HN2011002261A (enExample)
HR (1) HRP20130579T1 (enExample)
IL (1) IL214277A (enExample)
ME (1) ME01619B (enExample)
MX (1) MX2011008280A (enExample)
NI (1) NI201100160A (enExample)
NZ (1) NZ595248A (enExample)
PE (2) PE20151281A1 (enExample)
PL (1) PL2398780T3 (enExample)
PT (1) PT2398780E (enExample)
RS (1) RS52851B (enExample)
SA (1) SA110310136B1 (enExample)
SG (1) SG173449A1 (enExample)
SI (1) SI2398780T1 (enExample)
SM (1) SMT201300077B (enExample)
SV (1) SV2011004008A (enExample)
TW (1) TW201039825A (enExample)
UA (1) UA108841C2 (enExample)
UY (1) UY32460A (enExample)
WO (1) WO2010096011A1 (enExample)
ZA (1) ZA201106821B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655604C (en) * 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0815591B8 (pt) * 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
MX2012009537A (es) * 2010-02-18 2012-08-31 Astrazeneca Ab Formas solidas que comprenden un derivado de ciclopropilamida.
AU2011218491C1 (en) * 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
EP4215534B1 (en) 2020-09-18 2026-06-24 Carna Biosciences, Inc. Amine derivative
CN114790186B (zh) * 2021-01-25 2026-04-28 武汉人福创新药物研发中心有限公司 作为ep4拮抗剂的稠环化合物及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (enExample) * 1963-04-04 1900-01-01
NL128365C (enExample) 1963-11-05
US3449427A (en) * 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) * 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
CA2033390A1 (en) * 1989-12-29 1991-06-30 Susumu Nakagawa 2-(2-cyclopropylpyrrolidin-4-ylthio) carbapenem derivatives
EP0603240B1 (en) 1991-08-22 1998-12-02 Monsanto Company Safening herbicidal pyrazolylsulfonylureas
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
ATE202109T1 (de) 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)
EP0793653A1 (en) 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
EP0968200A1 (en) 1997-02-24 2000-01-05 ZymoGenetics, Inc. Calcitonin mimetics
US6160134A (en) 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
WO2000000492A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha FINE POWDER OF L-α-AMINOADIPIC ACID DERIVATIVE, ORAL SOLID PREPARATIONS CONTAINING THE SAME, AND METHOD FOR TREATMENT OF BULK POWDERS
AU771199B2 (en) 1999-01-08 2004-03-18 Neurogen Corporation 1-phenyl-4-(1-(2-aryl)cyclopropyl) methylpiperazines: dopamine receptor ligands
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
AU5426500A (en) 1999-06-16 2001-01-02 Takeda Chemical Industries Ltd. Benzazepine derivatives, process for the preparation of the same and uses thereof
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
WO2002002522A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
IL153884A0 (en) 2000-07-20 2003-07-31 Neurogen Corp Capsaicin receptor ligands
JPWO2002051781A1 (ja) 2000-12-25 2004-04-22 味の素株式会社 光学活性ハロヒドリン化合物の製造方法
MXPA03007621A (es) 2001-02-23 2003-12-04 Merck & Co Inc Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
EP1422228A1 (en) 2001-08-08 2004-05-26 Takeda Chemical Industries, Ltd. BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
WO2003026572A2 (en) 2001-09-26 2003-04-03 Merck & Co., Inc. Crystalline forms of ertapenem sodium
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2005526800A (ja) 2002-03-22 2005-09-08 エルジー・ライフ・サイエンシーズ・リミテッド (2S)−N−5−[アミノ(イミノ)メチル]−2−チエニルメチル−1−(2R)−2−[(カルボキシルメチル)アミノ]−3,3−ジフェニルプロパノイル−2−ピロリジンカルボキサミド・nH2Oの新しい結晶形
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
US20040077618A1 (en) 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) * 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
AU2003284402A1 (en) 2002-11-15 2004-06-15 Yamanouchi Pharmaceutical Co., Ltd. Antagonist to melanin-concentrating hormone receptor
ES2298627T3 (es) 2002-12-13 2008-05-16 Smithkline Beecham Corporation Compuestos de ciclopropilo como antagonistas de ccr5.
HRP20080541T3 (en) 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
EP1617840A4 (en) 2003-05-01 2008-08-20 Bristol Myers Squibb Co PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ZA200605248B (en) 2003-12-15 2007-10-31 Japan Tobacco Inc Cyclopropane compounds and pharmaceutical use thereof
BRPI0418939A (pt) 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
BRPI0515851A (pt) 2004-09-29 2008-08-12 Mitsubishi Pharma Corp composto de pirimidona
US20080045506A1 (en) 2004-10-15 2008-02-21 Glaxo Group Limited Pyrrolidine Derivatives as Histamine Receptors Ligands
BRPI0517423A (pt) 2004-12-27 2008-10-07 Astrazeneca Ab composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
CA2595882A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
JP2008530162A (ja) 2005-02-15 2008-08-07 グラクソ グループ リミテッド グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
WO2006100591A1 (en) 2005-03-25 2006-09-28 Pharmacia & Upjohn Company Llc 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602227A1 (en) 2005-03-28 2006-10-05 Michael Dalton Ennis 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
EP1896483A2 (en) 2005-03-28 2008-03-12 Pharmacia & Upjohn Company LLC 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602538A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CN101263125A (zh) 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
KR101336106B1 (ko) * 2005-09-16 2013-12-05 얀센 파마슈티카 엔.브이. 히스타민 h3 수용체의 조절제로서 사이클로프로필 아민
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
DK1951699T3 (da) 2005-10-31 2013-01-14 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af cyclopropylamidderivater
WO2007075895A2 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
CN101384581B (zh) 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
US20100006010A1 (en) 2006-03-01 2010-01-14 Ihor Hinczak Matrix for masonry elements and method of manufacture thereof
JP2009132621A (ja) 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
AU2007231594A1 (en) 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007138928A1 (ja) 2006-05-26 2007-12-06 Kaneka Corporation 光学活性3-アミノ-2-ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法
CA2655604C (en) * 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2007271187A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
US20090247499A1 (en) 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
TW200828371A (en) 2006-09-21 2008-07-01 Matsushita Electric Industrial Co Ltd Chip-type filter
DE102006056526A1 (de) 2006-11-30 2008-06-05 Archimica Gmbh Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
JP2010529157A (ja) * 2007-06-11 2010-08-26 エフ.ホフマン−ラ ロシュ アーゲー シクロヘキシル誘導体
BRPI0815591B8 (pt) * 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
AR070107A1 (es) 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
DE102008049371A1 (de) 2008-03-06 2009-09-10 Mühlbauer Ag Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
CA2721303C (en) 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
JP2012503595A (ja) 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
CN101462980B (zh) 2009-01-05 2013-01-09 扬州天辰精细化工有限公司 2,6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
AU2011218491C1 (en) * 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
MX2012009537A (es) * 2010-02-18 2012-08-31 Astrazeneca Ab Formas solidas que comprenden un derivado de ciclopropilamida.

Also Published As

Publication number Publication date
HK1208348A1 (en) 2016-03-04
BRPI1007817A2 (pt) 2017-05-30
KR20110126628A (ko) 2011-11-23
PT2398780E (pt) 2013-06-25
CR20110447A (es) 2011-09-19
JP5666480B2 (ja) 2015-02-12
CO6400219A2 (es) 2012-03-15
SA110310136B1 (ar) 2014-01-14
NI201100160A (es) 2012-03-15
CU20110161A7 (es) 2012-02-15
US20150164888A1 (en) 2015-06-18
EP2398780A4 (en) 2012-09-19
ME01619B (me) 2014-09-20
IL214277A0 (en) 2011-09-27
SI2398780T1 (sl) 2013-08-30
ECSP11011280A (es) 2011-09-30
EP2398780B1 (en) 2013-04-17
DOP2011000270A (es) 2012-08-31
CA2752796A1 (en) 2010-08-26
WO2010096011A1 (en) 2010-08-26
NZ595248A (en) 2014-01-31
TW201039825A (en) 2010-11-16
SV2011004008A (es) 2012-01-06
JP2015071634A (ja) 2015-04-16
CN104398516A (zh) 2015-03-11
MX2011008280A (es) 2011-08-24
JP2012518634A (ja) 2012-08-16
UA108841C2 (ru) 2015-06-25
ES2416464T3 (es) 2013-08-01
EA020093B1 (ru) 2014-08-29
EA201490268A1 (ru) 2015-07-30
CU20140013A7 (es) 2014-04-24
EP2398780A1 (en) 2011-12-28
PE20151281A1 (es) 2015-10-04
US20100216812A1 (en) 2010-08-26
HRP20130579T1 (en) 2013-07-31
HN2011002261A (es) 2014-07-31
PE20120063A1 (es) 2012-03-04
US8993577B2 (en) 2015-03-31
UY32460A (es) 2010-09-30
AR075531A1 (es) 2011-04-06
EA201190140A1 (ru) 2012-03-30
DK2398780T3 (da) 2013-07-01
CN102405213A (zh) 2012-04-04
HK1164863A1 (en) 2012-09-28
SG173449A1 (en) 2011-09-29
ZA201106821B (en) 2012-06-26
AU2010216454A1 (en) 2011-08-25
RS52851B (sr) 2013-12-31
AU2010216454B2 (en) 2013-05-02
CN102405213B (zh) 2014-11-19
IL214277A (en) 2015-08-31
US20150164889A1 (en) 2015-06-18
PL2398780T3 (pl) 2013-08-30

Similar Documents

Publication Publication Date Title
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
ECSP12011999A (es) Derivados benzamida sustituidos
HRP20161562T1 (hr) Derivati benzimidazola
BRPI1009280A2 (pt) bracadeira de riser
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BR112012008108A2 (pt) derivados de xantina substituídos
BRPI0914544A2 (pt) derivados de pirimidona substituídos
EP2462134A4 (en) N1-sulfonyl-5-FLUORPYRIMIDINON DERIVATIVES
BRPI1011468A2 (pt) derivados condensados de pirrolipiridino
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2397480T3 (da) Diazepindionderivat
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BR112012002336A2 (pt) compostos aza-heterocíclicos
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
SMT201400080B (it) Derivati di pirazinoossazepina
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
BRPI0922652A2 (pt) Derivados de quinazolinamida
DK2387580T3 (da) Deoxyactagardinderivater
BRPI0820779A2 (pt) Derivados de 4-amino-pirimidina
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
ECSP12011977A (es) Derivados de etinilo